Cargando…

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis

BACKGROUND/OBJECTIVES: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild‐to‐moderate atopic dermatitis (AD). This pooled post hoc analysis of two phase 3 trials (NCT02118766, NCT02118792) assessed improvement and time to improvement in Investigator&#...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eichenfield, Lawrence F., Yosipovitch, Gil, Stein Gold, Linda F., Kalabis, Mizuho, Zang, Chuanbo, Vlahos, Bonnie, Sanders, Paul, Myers, Daniela E., Bushmakin, Andrew G., Cappelleri, Joseph C., Olivadoti, Melissa, Paller, Amy S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756882/ https://www.ncbi.nlm.nih.gov/pubmed/32981097 http://dx.doi.org/10.1111/pde.14328

Ejemplares similares

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
por: Thyssen, Jacob P., et al.
Publicado: (2021)

Crisaborole for atopic dermatitis
Publicado: (2019)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study
por: Eichenfield, Lawrence F., et al.
Publicado: (2023)

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
por: Thom, Howard, et al.
Publicado: (2021)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023)

Relationship Among Treatment, Pruritus, Investigator’s Static Global Assessment, and Quality of Life in Patients with Atopic Dermatitis
por: Simpson, Eric L., et al.
Publicado: (2021)

Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis
por: Smith, Mary Patricia, et al.
Publicado: (2019)

Tacrolimus ointment in the management of atopic dermatitis
por: Baldo, Antonello, et al.
Publicado: (2009)

Response to the Letter to the Editor Regarding “Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systemic Literature Review and Network Meta-Analysis”
por: Fahrbach, Kyle, et al.
Publicado: (2021)

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis
por: Simpson, Eric L., et al.
Publicado: (2022)

Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
por: Hall, Rebecca, et al.
Publicado: (2021)

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
por: SILVERBERG, Jonathan I., et al.
Publicado: (2020)

Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus
por: Teresiak-Mikołajczak, Ewa, et al.
Publicado: (2013)

Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
por: Hall, Rebecca, et al.
Publicado: (2021)

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Letter to the Editor Regarding ‘Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis’
por: Luger, Thomas, et al.
Publicado: (2021)

What’s New in Topicals for Atopic Dermatitis?
por: Kleinman, Elana, et al.
Publicado: (2022)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis
por: PAVLENKO, Darya, et al.
Publicado: (2023)

Tolerability of Topical Treatments for Atopic Dermatitis
por: Draelos, Zoe D., et al.
Publicado: (2019)

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)
por: Schlessinger, Joel, et al.
Publicado: (2020)

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
por: Yosipovitch, G., et al.
Publicado: (2019)

Neuroimmune interactions in chronic itch of atopic dermatitis
por: Yosipovitch, G., et al.
Publicado: (2019)

Neuroimmunological Mechanism of Pruritus in Atopic Dermatitis Focused on the Role of Serotonin
por: Kim, Kwangmi
Publicado: (2012)

The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
por: Rerknimitr, Pawinee, et al.
Publicado: (2017)

Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
por: Labib, Angelina, et al.
Publicado: (2022)

The microbiome in patients with atopic dermatitis
por: Paller, Amy S., et al.
Publicado: (2018)

Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis
por: Paller, Amy S., et al.
Publicado: (2022)

Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: A case series
por: Hosono, Shusaku, et al.
Publicado: (2020)

The severity of atopic dermatitis evaluated with the SCORAD index and the occurrence of bronchial asthma and rhinitis, and the duration of atopic dermatitis
por: Celakovská, Jarmilă, et al.
Publicado: (2016)

Influence of Weight Loss on Severity of Atopic Dermatitis in a 20-Year-Old Female with Atopic Dermatitis
por: Son, Jee Hee, et al.
Publicado: (2018)

Transcutaneous Slowly Depolarizing Currents Elicit Pruritus in Patients with Atopic Dermatitis
por: RUKWIED, Roman, et al.
Publicado: (2020)

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l5rggc9dn30pktt432lqqm8miq